Medindia

X

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis

Tuesday, November 24, 2009 General News J E 4
Advertisement

Contacts:

Cephalon:

Media:

Investor Relations:

Sheryl Williams

Chip Merritt

610-738-6493 (office)

610-738-6376 (office)

610-457-5257 (cell)

cmerritt@cephalon.com

swilliam@cephalon.com

Ception:

Media: Mike Beyer - Sam Brown Inc.

773-463-4211 (office)

beyer@sambrown.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Sagent Pharmaceuticals to Present at Piper Jaffray...
S
Milwaukee Employers See Cost Savings with High-Per...